Conditions: Healthy
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 80
Healthy volunteers: yes

Brief summary:
The primary objective is to investigate the safety, tolerability and pharmacokinetics of BI 655075 following intravenous administration of single rising doses of BI 655075 when administered alone and after administration of dabigatran.

Detailed description:

Arms:
arm 1: different infusion durations arm 2: short infusion with 2 capsules dabigatran

Interventions: intervention 1: Placebo to dose intervention 2: Idarucizumab intervention 3: Placebo to Idarucizumab intervention 4: dabigatran intervention 5: Idarucizumab
Intervention descriptions: intervention 1: placebo intervention 2: short infusion intervention 3: Placebo to Idarucizumab intervention 4: 2 capsules dabigatran intervention 5: short infusion

Protocol document: